Life Science Nation Newsletter  |  March 24, 2016  |  Issue 155

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Mar. 17 - Mar. 23)
Seeks Healthcare IT & Mobile Health Technologies
Seeks Therapeutics and Medical Devices in Oncology, Immunology and Hematology
Seeks HCIT, Health Services, and Life Science Companies
Seeks Therapeutics In Oncology, Dermatology, Rare Diseases, and Acute Care
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of [email protected] 2015

By Christine A. Wu, Research Analyst, LSN

The Lobster Pot was boiling last Wednesday at the Women in Bio and Johnson & Johnson Innovation Shark Tank-style pitch event in Cambridge, MA. Organized by the LSN team, eight female life science CEOs gave 6-minute pitches proceeded by short sessions of feedback from five female investors.

So how hot did the "chef" investors boil these "lobster" CEOs? Below are common critiques to fundraising entrepreneurs - be sure to take these into account for your next presentation.

Address your Audience

Keep in mind who your audience is and tailor your message appropriately. Take into account their background and expertise...

By Cole Bunn, Research Analyst, LSN

The diagnostics space encompasses a very wide range of technologies targeting indications across the board, and is arguably the most difficult sector, under the life science umbrella, to successfully navigate. Not only do these entrepreneurs have to first identify the correct capital providers and strategic partners to make their technologies a commercial reality, like everyone else, but piquing the interests of those entities may be considerably more difficult. Oftentimes, clearly articulating the value proposition of your diagnostic product/service is a little trickier than that of a more traditional therapeutic or medical device, and the go-to-market strategy for these technologies will usually be more highly scrutinized.

Moderated by John Walter, CEO & President, Alliance for Cancer Gene Therapy Foundation, this session will feature:
  • Wouter Meuleman, Director, Corporate & Venture Development, Illumina
  • Caroline Popper, President, BCM Technologies
  • Tom Miller, Managing Partner, Greybird Ventures
  • Tom Hawes, Managing Director, Sandbox Industries
By Lucy Parkinson, Director of Research, LSN

Medtech innovation is one of the focuses of Texas Medical Center's innovation programs, with TMCx focusing its startup acceleration program on medical devices and healthcare IT. [email protected] will provide a venue for investors to meet with innovative medical device startups from Texas and beyond, and this panel session will explore what it takes to get a new device product funded and commercialized.

Moderated by Angela Shah, Editor, Xconomy, the panelists are:
  • Philip Sanger, Managing Partner, Texo Ventures
  • Steve Banks, Venture Partner Emeritus, S3 Ventures
  • James Eadie, Partner, Santé Ventures
  • Andrew Offer, Chief Financial Officer & Managing Director, Scientific Health Development Partners

Life Science Nation | 9B Hamilton Place | Boston | MA | 02108